(St. Jude Children’s Research Hospital) St. Jude Children’s Research Hospital-led study expands understanding of the genetic basis of acute lymphoblastic leukemia subtypes and identifies possible targeted therapy for some patients at risk for a poor outcome.
Publication date: August 2018Source: Seminars in Cancer Biology, Volume 51Author(s): Jessica Nordlund, Ann-Christine SyvänenAbstractAcute lymphoblastic leukemia (ALL) is the most common malignancy in children. ALL arises from the malignant transformation of progenitor B- and T-cells in the bone marrow into leukemic cells, but the mechanisms underlying this transformation are not well understood. Recent technical advances and decreasing costs of methods for high-throughput DNA sequencing and SNP genotyping have stimulated systematic studies of the epigenetic changes in leukemic cells from pediatric ALL patients. The re…
AbstractPurpose of ReviewTreatment options for patients with acute lymphoblastic leukemia (ALL) beyond standard chemotherapy have grown significantly in recent years. In this review, we highlight new targeted therapies in ALL, with an emphasis on immunotherapy.Recent FindingsMajor advances include antibody-based therapies, such as naked monoclonal antibodies, antibody-drug conjugates and bispecific T cell engaging (BiTE) antibodies, as well as adoptive cellular therapies such as chimeric antigen receptor (CAR) T cells. Apart from the above immunotherapeutic approaches, other targeted therapies are being employed in Philade…
Condition: Leukemia, B-cell Intervention: Biological: CART-19/22 Sponsors: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; The First Affiliated Hospital of Soochow University Recruiting
Authors: Mattison RJ
On March 29, 2018, blinatumomab (Blincyto, Amgen) received an accelerated expanded approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in first or second complete remission (CR) and have minimal residual disease (MRD). Blinatumomab was first approved for use in adult patients (in December 2014) and later in pediatric patients (in September 2016) with relapsed or refractory Philadelphia chromosome (Ph)-negative B-cell precursor ALL; the approval was expanded in July 2017 to include patients with Ph-positive disease….
This article emphasizes the specific pediatric aspects of long-term aftercare following myeloablative HSCT and provides an organ-based overview that covers main clinical patterns, incidence, and risk factors enhanced by current references and screening guidelines.Recent FindingsIn the last years, several attempts were made to separate pediatric outcome data from findings in adults. It turned out that not only the indication for but also the time and the procedures of HSCT substantially differ. Nearly any organ might be affected after the complex transplantation process and includes endocrinopathies, musculoskeletal disorde…
We report the case of a 61-year-old Caucasian man with a history of alcoholic cirrhosis and numerous, large, and extensive basal cell carcinomas who was started on vismodegib, and presented 2 weeks later with altered mental status and hypercalcemia, hyperuricemia, and high LDH.
Langerhans cells (LCs) are a type of dendritic cell that characteristically express S100, CD1a, and langerin (CD207). Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of cells with the phenotype of activated LCs. Rarely, LCH may be associated with various hematologic neoplasms including acute lymphoblastic and myeloid leukemias, other clonal myeloid neoplasms, and lymphomas. Acute lymphoblastic leukemia is more often associated with LCH in children, whereas lymphoma and acute myeloid leukemia (AML) are more common in adults, which may reflect the frequency of these diseases in the respective populations.
The Bruton tyrosine kinase inhibitor ibrutinib induces high rates of clinical response in chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments to deepen response and to overcome drug resistance. Blinatumomab, a CD19/CD3 bispecific antibody (bsAb) designed in the BiTE (bispecific T-cell engager) format, is approved by the US Food and Drug Administration for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Because of its short half-life of 2.1 hours, blinatumomab requires continuous intravenous dosing for efficacy. We developed a novel CD19/CD3 bsAb in…
Condition: Acute Lymphoid Leukemia Intervention: Drug: Inotuzumab Ozogamicin (IO) Sponsor: Gruppo Italiano Malattie EMatologiche dell’Adulto Not yet recruiting
In this study, we show for the first time that PHF6 is a master regulator of early hematopoietic differentiation along the T-cell, B-cell, myeloid and NK-cell lineages.